Circovirus sequences associated with piglet weight loss disease (PWD)
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1 . A vaccine comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle, wherein the nucleotide sequence is selected from SEQ ID No. 15 or SEQ ID No. 19.
2 . The vaccine of claim 1 , wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.
3 . A vaccine comprising a polypeptide encoded by a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
4 . The vaccine of claim 3 , wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.
5 . The vaccine of claim 3 , wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
6 . The vaccine of claim 5 , wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No. 25.
7 . The vaccine of claim 5 , wherein the nucleotide sequence is SEQ ID No. 25.
8 . The vaccine of claim 3 , wherein the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No. 26.
9 . The vaccine of claim 8 , wherein the polypeptide has the amino acid sequence of SEQ ID No. 26.
10 . The vaccine of claim 3 , wherein the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No. 26.
11 . The vaccine of claim 10 , wherein the homologue has at least 80% sequence identity to SEQ ID No. 26.
12 . The vaccine of claim 3 , wherein the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32.
13 . A vaccine comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.
14 . A vaccine according to claim 13 , further comprising a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.
15 . A vaccine comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.
16 . A vaccine comprising a pharmaceutically acceptable vehicle and a single polypetide, wherein the single polypeptide consists of SEQ ID No. 26.